دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Mending Broken Hearts
Bonnie L. Bermas, Vlad G. Zaha
doi : 10.1161/CIRCULATIONAHA.120.052307
Circulation. 2021;143:767–769
Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
Chintan V. Dave, Seoyoung C. Kim, Allison B. Goldfine, Robert J. Glynn, Angela Tong, Elisabetta Patorno
doi : 10.1161/CIRCULATIONAHA.120.047965
Circulation. 2021;143:770–779
Several glucagon-like peptide receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefit in type 2 diabetes in large randomized controlled trials in patients with established cardiovascular disease or multiple risk factors. However, few trial participants were on both agents, and it remains unknown whether the addition of SGLT2i to GLP-1RA therapy has further cardiovascular benefits.
Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?
Alice Y.Y. Cheng
doi : 10.1161/CIRCULATIONAHA.120.053058
Circulation. 2021;143:780–782
Central Command and the Regulation of Exercise Heart Rate Response in Heart Failure With Preserved Ejection Fraction
Satyam Sarma, Erin Howden, Justin Lawley, Mitchel Samels, Benjamin D. Levine
doi : 10.1161/CIRCULATIONAHA.120.048338
Circulation. 2021;143:783–789
Chronotropic incompetence is common in heart failure with preserved ejection fraction (HFpEF) and is linked to impaired aerobic capacity. Whether upstream autonomic signaling pathways responsible for raising exercise heart rate are impaired in HFpEF is unknown. We investigated the integrity of central command and muscle metaboreceptor function, 2 predominant mechanisms responsible for exertional increases in heart rate, in patients with HFpEF and senior controls.
Myocardial Infarction in the ISCHEMIA Trial
Bernard R. Chaitman, Karen P. Alexander, Derek D. Cyr, Jeffrey S. Berger, Harmony R. Reynolds, Sripal Bangalore, William E. Boden, Renato D. Lopes, Marcin Demkow, Gian Piero Perna, Robert K. Riezebos, Edward O. McFalls, Subhash Banerjee, Akshay Bagai, Gilbert Gosselin, Sean M. O’Brien, Frank W. Rockhold, David D. Waters, Kristian A. Thygesen, Gregg W. Stone, Harvey D. White, David J. Maron, Judith S. Hochman, and On behalf of the ISCHEMIA Research Group
doi : 10.1161/CIRCULATIONAHA.120.047987
Circulation. 2021;143:790–804
In the ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches), an initial invasive strategy did not significantly reduce rates of cardiovascular events or all-cause mortality in comparison with a conservative strategy in patients with stable ischemic heart disease and moderate/severe myocardial ischemia. The most frequent component of composite cardiovascular end points was myocardial infarction (MI).
Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling
Naoko Yamaguchi, Junhua Xiao, Deven Narke, Devin Shaheen, Xianming Lin, Erik Offerman, Alireza Khodadadi-Jamayran, Akshay Shekhar, Alex Choy, Sojin Y. Wass, David R. Van Wagoner, Mina K. Chung, David S. Park
doi : 10.1161/CIRCULATIONAHA.120.048121
Circulation. 2021;143:805–820
Elevated intracardiac pressure attributable to heart failure induces electrical and structural remodeling in the left atrium (LA) that begets atrial myopathy and arrhythmias. The underlying molecular pathways that drive atrial remodeling during cardiac pressure overload are poorly defined. The purpose of this study is to characterize the response of the ETV1 (ETS translocation variant 1) signaling axis in the LA during cardiac pressure overload in humans and mouse models and explore the role of ETV1 in atrial electrical and structural remodeling.
Cross-Priming Dendritic Cells Exacerbate Immunopathology After Ischemic Tissue Damage in the Heart
Elvira Forte, Bryant Perkins, Amalia Sintou, Harkaran S. Kalkat, Angelos Papanikolaou, Catherine Jenkins, Mashael Alsubaie, Rasheda A. Chowdhury, Theodore M. Duffy, Daniel A. Skelly, Jane Branca, Mohamed Bellahcene, Michael D. Schneider, Sian E. Harding, Milena B. Furtado, Fu Siong Ng, Muneer G. Hasham, Nadia Rosenthal, Susanne Sattler
doi : 10.1161/CIRCULATIONAHA.120.044581
Circulation. 2021;143:821–836
Ischemic heart disease is a leading cause of heart failure and despite advanced therapeutic options, morbidity and mortality rates remain high. Although acute inflammation in response to myocardial cell death has been extensively studied, subsequent adaptive immune activity and anti-heart autoimmunity may also contribute to the development of heart failure. After ischemic injury to the myocardium, dendritic cells (DC) respond to cardiomyocyte necrosis, present cardiac antigen to T cells, and potentially initiate a persistent autoimmune response against the heart. Cross-priming DC have the ability to activate both CD4+ helper and CD8+ cytotoxic T cells in response to necrotic cells and may thus be crucial players in exacerbating autoimmunity targeting the heart. This study investigates a role for cross-priming DC in post–myocardial infarction immunopathology through presentation of self-antigen from necrotic cardiac cells to cytotoxic CD8+ T cells.
Bending the Curve in Cardiovascular Disease Mortality
David Calvin Goff Jr, Sadiya Sana Khan, Donald Lloyd-Jones, Donna K. Arnett, Mercedes R. Carnethon, Darwin R. Labarthe, Matthew Shane Loop, Russell V. Luepker, Michael V. McConnell, George A. Mensah, Mahasin S. Mujahid, Martin Enrique O’Flaherty, Dorairaj Prabhakaran, Véronique Roger, Wayne D. Rosamond, Stephen Sidney, Gina S. Wei, Janet S. Wright
doi : 10.1161/CIRCULATIONAHA.120.046501
Circulation. 2021;143:837–851
More than 40 years after the 1978 Bethesda Conference on the Declining Mortality from Coronary Heart Disease provided the scientific community with a blueprint for systematic analysis to understand declining rates of coronary heart disease, there are indications the decline has ended or even reversed despite advances in our knowledge about the condition and treatment. Recent data show a more complex situation, with mortality rates for overall cardiovascular disease, including coronary heart disease and stroke, decelerating, whereas those for heart failure are increasing. To mark the 40th anniversary of the Bethesda Conference, the National Heart, Lung, and Blood Institute and the American Heart Association cosponsored the “Bending the Curve in Cardiovascular Disease Mortality: Bethesda + 40” symposium. The objective was to examine the immediate and long-term outcomes of the 1978 conference and understand the current environment. Symposium themes included trends and future projections in cardiovascular disease (in the United States and internationally), the evolving obesity and diabetes epidemics, and harnessing emerging and innovative opportunities to preserve and promote cardiovascular health and prevent cardiovascular disease. In addition, participant-led discussion explored the challenges and barriers in promoting cardiovascular health across the lifespan and established a potential framework for observational research and interventions that would begin in early childhood (or ideally in utero). This report summarizes the relevant research, policy, and practice opportunities discussed at the symposium.
Highlights From the Circulation Family of Journals
doi : 10.1161/CIRCULATIONAHA.121.053936
Circulation. 2021;143:852–856
A Case of Presyncope After Transcatheter Aortic Valve Replacement
Virginia Workman, John K. Forrest, Alan Enriquez
doi : 10.1161/CIRCULATIONAHA.120.049693
Circulation. 2021;143:857–861
When You Hear Hoofbeats, Look for Horses, Not Zebras
Dursun Aras, Ozcan Ozeke, Serkan Topaloglu
doi : 10.1161/CIRCULATIONAHA.120.052468
Circulation. 2021;143:862–864
Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells
Ian R. McCracken, Gaye Saginc, Liqun He, Alik Huseynov, Alison Daniels, Sarah Fletcher, Claire Peghaire, Viktoria Kalna, Maarja Andaloussi-M?e, Lars Muhl, Nicky M. Craig, Samantha J. Griffiths, Jürgen G. Haas, Christine Tait-Burkard, Urban Lendahl, Graeme M. Birdsey, Christer Betsholtz, Michela Noseda, Andrew H. Baker, Anna M. Randi
doi : 10.1161/CIRCULATIONAHA.120.052824
Circulation. 2021;143:865–868
Association of Cigarette and Electronic Cigarette Use Patterns With Levels of Inflammatory and Oxidative Stress Biomarkers Among US Adults
Andrew C. Stokes, Wubin Xie, Anna E. Wilson, Hanqi Yang, Olusola A. Orimoloye, Alyssa F. Harlow, Jessica L. Fetterman, Andrew P. DeFilippis, Emelia J. Benjamin, Rose Marie Robertson, Aruni Bhatnagar, Naomi M. Hamburg, Michael J. Blaha
doi : 10.1161/CIRCULATIONAHA.120.051551
Circulation. 2021;143:869–871
Screening for Fabry Disease in Male Patients With Arrhythmia Requiring a Pacemaker or an Implantable Cardioverter–Defibrillator
Dimitri Hemelsoet, Jan De Keyser, Frederic Van Heuverswyn, Rik Willems, Hans Vandekerckhove, Antoine Bondue, Carlo de Asmundis, Johan Saenen, Stefaan Van de Walle, Pascal Godart, Christoph Kampmann, Hedwig Stepman, Bruce Poppe, Wim Terryn
doi : 10.1161/CIRCULATIONAHA.120.051400
Circulation. 2021;143:872–874
Letter by Putot et al Regarding Article, “Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction”
Alain Putot, Yves Cottin, Marianne Zeller
doi : 10.1161/CIRCULATIONAHA.120.051103
Circulation. 2021;143:e250–e251
Response by Horiuchi et al to Letter Regarding Article, “Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction”
Yu Horiuchi, Nicholas Wettersten, Alan Maisel
doi : 10.1161/CIRCULATIONAHA.120.051634
Circulation. 2021;143:e252–e253
Heart Disease and Stroke Statistics—2021 Update
Salim S. Virani, Alvaro Alonso, Hugo J. Aparicio, Emelia J. Benjamin, Marcio S. Bittencourt, Clifton W. Callaway, April P. Carson, Alanna M. Chamberlain, Susan Cheng, Francesca N. Delling, Mitchell S.V. Elkind, Kelly R. Evenson, Jane F. Ferguson, Deepak K. Gupta, Sadiya S. Khan, Brett M. Kissela, Kristen L. Knutson, Chong D. Lee, Tené T. Lewis, Junxiu Liu, Matthew Shane Loop, Pamela L. Lutsey, Jun Ma, Jason Mackey, Seth S. Martin, David B. Matchar, Michael E. Mussolino, Sankar D. Navaneethan, Amanda Marma Perak, Gregory A. Roth, Zainab Samad, Gary M. Satou, Emily B. Schroeder, Svati H. Shah, Christina M. Shay, Andrew Stokes, Lisa B. VanWagner, Nae-Yuh Wang, Connie W. Tsao, and On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee See fewer authors
doi : 10.1161/CIR.0000000000000950
Circulation. 2021;143:e254–e743
The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health. The Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, congenital heart disease, rhythm disorders, subclinical atherosclerosis, coronary heart disease, heart failure, valvular disease, venous disease, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs).
Correction to: Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
doi : 10.1161/CIR.0000000000000964
Circulation. 2021;143:e744
Correction to: Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling
doi : 10.1161/CIR.0000000000000951
Circulation. 2021;143:e745
